Blockade of excitatory amino acid receptors in the ventrolateral medulla does not abolish the cardiovascular actions of L-glutamate.
Injection of L-glutamate into the caudal ventrolateral medulla reduces arterial pressure while injection of L-glutamate into the rostral ventrolateral medulla increases arterial pressure. The present experiments were undertaken to determine whether blockade of excitatory amino acid receptor subtypes in the ventrolateral medulla affects the excitatory action of L-glutamate. In the rabbit and rat caudal ventrolateral medulla, injection of either DL-2-amino-5-phosphonovaleric acid (APV), an N-methyl-D-aspartic acid (NMDA) antagonist, or 6,7-dinitroquinoxaline-2,3-dione (DNQX), an alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, increased arterial pressure. Conversely, in the rostral ventrolateral medulla these agents decreased arterial pressure. In the rabbit caudal ventrolateral medulla, injection of APV totally blocked the depressor response to NMDA, and injection of DNQX totally blocked the depressor response to either kainic acid or AMPA. Injection of both APV and DNQX abolished the effects of NMDA, kainic acid and AMPA. However caudal ventrolateral medulla injection of either APV or DNQX, or combined injection of both antagonists, did not affect the relationship between the dose of L-glutamate and the fall in arterial pressure. Similarly, in the rat, combined excitatory amino acid receptor blockade failed to reduce the depressor effect of injected L-glutamate to the caudal ventrolateral medulla. The pressor effect of L-glutamate in the rabbit rostral ventrolateral medulla, when expressed as percentage of baseline level, was unchanged by combined excitatory amino acid receptor blockade.(ABSTRACT TRUNCATED AT 250 WORDS)
Gieroba
Z J
ZJ
Department of Medicine, Flinders University of South Australia, Bedford Park.
Blessing
W W
WW
D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates / Q000008:administration & dosage; D018698:Glutamic Acid; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects*; D008845:Microinjections; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011916:Rats, Inbred F344; D017459:Receptors, Amino Acid / Q000037:antagonists & inhibitors*
D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates; D011810:Quinoxalines; D017459:Receptors, Amino Acid; D018698:Glutamic Acid; C056723:FG 9041; D015763:2-Amino-5-phosphonovalerate